Navigation Links
IADR/AADR Journal of Dental Research releases large studies on osteonecrosis of the jaw
Date:2/11/2011

Alexandria, VA Osteonecrosis of the jaw (ONJ) is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors. Today, the International and American Associations for Dental Research's Journal of Dental Research (JDR) released a research report that estimates the prevalence of the disease, and a case-control study on bisphosphonate use and other risk factors. These investigations published in the JDR represent some of the largest published studies to date on ONJ patients, and the researchers involved utilized the National Institute of Dental and Craniofacial Research-supported Practice-based Research Networks (PBRNs).

In a JDR article titled "Risk Factors for Osteonecrosis of the Jaws: a Case-control Study," authors A. Barasch, J. Cunha-Cruz, F.A. Curro, P. Hujoel, A.H. Sung, D. Vena and A.E. Voinea-Griffin conducted a case-control study with three DPBRNs to determine the risk associated with bisphosphonates and identify other risk factors for ONJ, including dental diseases and procedures. Researchers enrolled 191 ONJ cases and 573 controls from 119 dental practices. Bisphosphonate use was strongly associated with ONJ with an odds ratio of 299.5 for intravenous use and 12.2 for oral use.

In a second JDR article titled "ONJ in Two Dental Practice-Based Research Network Regions," authors J.L. Fellows, D.B. Rindal, A. Barasch, C.M. Gullion, W. Rush, D.J. Pihlstrom and J. Richman conducted a Dental Practice-based Research Network (DPBRN) study that estimated ONJ incidence and odds ratios from bisphosphonate exposure and other risk factors using patients' electronic records. The researchers identified 572,606 health plan members and of those patients, approximately 25,000 had a diagnosis or procedure code that suggested a necrotic bone lesion, including inflammatory jaw condition, cyst of bone, aseptic necrosis of the bone and open wound of the jaw. Of those members' electronic medical records, 73 suspected ONJ cases were identified, of which 16 were later confirmed by manual chart review. An additional seven cases were indentified through oral surgeons or the Peer Review Committee for a total of 23 confirmed ONJ cases. Patients with oral bisphosphonates were 15.5 times more likely to have ONJ than non-exposed patients. However, the number of ONJ cases limits firm conclusions and suggests absolute risks for ONJ from oral bisphosphonates is low.

"ONJ represents a challenging clinical dilemma affecting dental and cancer patients, and communities at many levels of dentistry, notably oral/maxillofacial surgery and oral oncology are called upon to manage these cases," stated JDR Editor-in-Chief William Giannobile. "The work underscores important clinical implications that will be of value to not only the IADR and AADR communities, but especially practicing clinicians.

A perspective article titled "Making a Case for Defining Osteonecrosis of the Jaw" was written by C. Van Posznak, breast cancer oncologist expert on the topic. In it, she summarizes the key implications of ONJ and the relevance in the field of the two JDR research reports. The research that was conducted may have an important impact to the developing of better definitions for ONJ.


'/>"/>

Contact: Ingrid L. Thomas
ithomas@iadr.org
703-299-8084
International & American Association for Dental Research
Source:Eurekalert

Related medicine news :

1. Over 40 new titles added to Wiley-Blackwells journals program in 2011
2. Elsevier acquires oncology journal portfolio from Cancer Information Group
3. American Chemical Society unveils International Year of Chemistry virtual journal
4. Journal of Vascular and Interventional Radiology debuts new look, reflects global impact
5. Elsevier announces new partnership with CCS to publish the Canadian Journal of Cardiology
6. French society for emergency medicine to publish official journal with Springer
7. Disability and Health Journal critically examines Americans with Disabilities Act
8. Elsevier launches new journal: Developmental Cognitive Neuroscience
9. New study: Serious gaps in medical journals disclosure of physician relationships with industry
10. Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation
11. Elsevier and International Society of Geriatric Oncology launch Journal of Geriatric Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Individuals who seek to ... as drinking more water or limiting their exposure to the sun, according to a ... beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures to help keep ...
(Date:12/6/2016)... ... December 06, 2016 , ... An inventor, from Talladega, Ala., thought there ... she invented the patent-pending SLING-VEST. , The SLING-VEST provides an effective way to support ... to traditional slings. As a result, it helps to reduce discomfort and shifting. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... health insights for population health management, announces today a strategic relationship with ... CitiusTech’s cloud-hosted clinical rules engine that offers advanced Clinical Quality Measures (CQM) ...
(Date:12/6/2016)... ... December 06, 2016 , ... It ... Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to check out ... resource. The expo’s beneficiary this year was Crossroads, a fully-accredited gender-responsive treatment ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new ... after launch. Almost 200 backers pledged more than $25,000 on Kickstarter ... , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology: